Journal of proteomics · 2020

An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments

Klatt MG, Aretz ZEH, Curcio M, Gejman RS, Jones HF, Scheinberg DA

Show affiliations
  • Klatt MGMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA.
  • Aretz ZEHMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA; Physiology Biophysics and Systems Biology Program, Weill Cornell Medicine, New York 10065, USA.
  • Curcio MMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA.
  • Gejman RSMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA; Tri-Institutional MD-PhD Program, Sloan Kettering Institute, Weill Cornell Medicine and Rockefeller University, New York 10065, USA.
  • Jones HFMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA; Pharmacology Department, Weill Cornell Medicine, New York 10065, USA.
  • Scheinberg DAMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York 10065, USA; Pharmacology Department, Weill Cornell Medicine, New York 10065, USA. Electronic address: scheinbd@mskcc.org.
1 read1 want to read

Characterization of MHC-bound peptides by mass spectrometry (MS) is an essential technique for immunologic studies. Many efforts have been made to quantify the number of MHC-presented ligands by MS and to define the limits of detection of a specific MHC ligand. However, these experiments are often complex and comparisons across different laboratories are challenging. Therefore, we compared and orthogonally validated quantitation of peptide:MHC complexes by radioimmunoassay and flow cytometry using TCR mimic antibodies in three model systems to establish a method to control the experimental input of peptide MHC:complexes for MS analysis. Following isolation of MHC-bound peptides we identified and quantified an MHC ligand of interest with high correlation to the initial input. We found that the diversity of the presented ligandome, as well as the peptide sequence itself affected the detection of the target peptide. Furthermore, results were applicable from these model systems to unmodified cell lines with a tight correlation between HLA-A*02 complex input and the number of identified HLA-A*02 ligands. Overall, this framework provides an easily accessible experimental setup that offers the opportunity to control the peptide:MHC input and in this way compare immunopeptidome experiments not only within but also between laboratories, independent of their experimental approach. SIGNIFICANCE: Although immunopeptidomics is an essential tool for the characterization of MHCbound peptides on the cell surface, there are no easily applicable established protocols available that allow comparison of immunopeptidome experiments across laboratories. Here, we demonstrate that controlling the peptide:MHC input for immunopurification and LC-MS/MS experiments by flow cytometry in pre-defined model systems allows the generation of qualitative and quantitative data that can easily be compared between investigators, independently of their methods for MHC ligand isolation for MS.

Most-cited papers citing this

  • Oncoimmunology · 2021 · cited by 25
  • Blood · 2022 · cited by 20

Log in to like, log, and share thoughts on this paper.

Discussion

Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.

0

Tristan Aretz

First paper -